Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 400

1.

Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers.

Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM.

Nature. 2009 Feb 26;457(7233):1128-32. doi: 10.1038/nature07761.

2.

Beta-amyloid oligomers and cellular prion protein in Alzheimer's disease.

Gunther EC, Strittmatter SM.

J Mol Med (Berl). 2010 Apr;88(4):331-8. doi: 10.1007/s00109-009-0568-7. Epub 2009 Dec 4. Review.

3.

Dextran sulfate sodium inhibits amyloid-β oligomer binding to cellular prion protein.

Aimi T, Suzuki K, Hoshino T, Mizushima T.

J Neurochem. 2015 Aug;134(4):611-7. doi: 10.1111/jnc.13166. Epub 2015 Jun 10.

PMID:
25963375
4.

Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein.

Balducci C, Beeg M, Stravalaci M, Bastone A, Sclip A, Biasini E, Tapella L, Colombo L, Manzoni C, Borsello T, Chiesa R, Gobbi M, Salmona M, Forloni G.

Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2295-300. doi: 10.1073/pnas.0911829107. Epub 2010 Jan 19.

5.

High molecular mass assemblies of amyloid-β oligomers bind prion protein in patients with Alzheimer's disease.

Dohler F, Sepulveda-Falla D, Krasemann S, Altmeppen H, Schlüter H, Hildebrand D, Zerr I, Matschke J, Glatzel M.

Brain. 2014 Mar;137(Pt 3):873-86. doi: 10.1093/brain/awt375. Epub 2014 Feb 10.

6.

N-methyl-D-aspartate receptors are required for synaptic targeting of Alzheimer's toxic amyloid-β peptide oligomers.

Decker H, Jürgensen S, Adrover MF, Brito-Moreira J, Bomfim TR, Klein WL, Epstein AL, De Felice FG, Jerusalinsky D, Ferreira ST.

J Neurochem. 2010 Dec;115(6):1520-9. doi: 10.1111/j.1471-4159.2010.07058.x. Epub 2010 Nov 11.

7.

Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins.

Pham E, Crews L, Ubhi K, Hansen L, Adame A, Cartier A, Salmon D, Galasko D, Michael S, Savas JN, Yates JR, Glabe C, Masliah E.

FEBS J. 2010 Jul;277(14):3051-67. doi: 10.1111/j.1742-4658.2010.07719.x. Epub 2010 Jun 22.

8.

The prion protein as a receptor for amyloid-beta.

Kessels HW, Nguyen LN, Nabavi S, Malinow R.

Nature. 2010 Aug 12;466(7308):E3-4; discussion E4-5. doi: 10.1038/nature09217.

9.

Alzheimer's disease: A prion protein connection.

Cisse M, Mucke L.

Nature. 2009 Feb 26;457(7233):1090-1. doi: 10.1038/4571090a. No abstract available.

PMID:
19242462
10.

Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits.

Izzo NJ, Staniszewski A, To L, Fa M, Teich AF, Saeed F, Wostein H, Walko T 3rd, Vaswani A, Wardius M, Syed Z, Ravenscroft J, Mozzoni K, Silky C, Rehak C, Yurko R, Finn P, Look G, Rishton G, Safferstein H, Miller M, Johanson C, Stopa E, Windisch M, Hutter-Paier B, Shamloo M, Arancio O, LeVine H 3rd, Catalano SM.

PLoS One. 2014 Nov 12;9(11):e111898. doi: 10.1371/journal.pone.0111898. eCollection 2014.

11.

Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity.

Izzo NJ, Xu J, Zeng C, Kirk MJ, Mozzoni K, Silky C, Rehak C, Yurko R, Look G, Rishton G, Safferstein H, Cruchaga C, Goate A, Cahill MA, Arancio O, Mach RH, Craven R, Head E, LeVine H 3rd, Spires-Jones TL, Catalano SM.

PLoS One. 2014 Nov 12;9(11):e111899. doi: 10.1371/journal.pone.0111899. eCollection 2014.

12.

Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons.

Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A, Wisniewski T, Gunther EC, Strittmatter SM.

Nat Neurosci. 2012 Sep;15(9):1227-35. doi: 10.1038/nn.3178. Epub 2012 Jul 22.

13.

Prion protein and Abeta-related synaptic toxicity impairment.

Calella AM, Farinelli M, Nuvolone M, Mirante O, Moos R, Falsig J, Mansuy IM, Aguzzi A.

EMBO Mol Med. 2010 Aug;2(8):306-14. doi: 10.1002/emmm.201000082.

14.

Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory.

Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ.

Nat Med. 2008 Aug;14(8):837-42. doi: 10.1038/nm1782. Epub 2008 Jun 22.

15.

Cellular prion protein as a therapeutic target in Alzheimer's disease.

Laurén J.

J Alzheimers Dis. 2014;38(2):227-44. doi: 10.3233/JAD-130950. Review.

PMID:
23948943
16.

Amyloid-β induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease.

Um JW, Strittmatter SM.

Prion. 2013 Jan-Feb;7(1):37-41. doi: 10.4161/pri.22212. Epub 2012 Sep 17. Review.

17.

PDK1 decreases TACE-mediated α-secretase activity and promotes disease progression in prion and Alzheimer's diseases.

Pietri M, Dakowski C, Hannaoui S, Alleaume-Butaux A, Hernandez-Rapp J, Ragagnin A, Mouillet-Richard S, Haik S, Bailly Y, Peyrin JM, Launay JM, Kellermann O, Schneider B.

Nat Med. 2013 Sep;19(9):1124-31. doi: 10.1038/nm.3302. Epub 2013 Aug 18.

PMID:
23955714
18.

Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of β-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices.

Rammes G, Hasenjäger A, Sroka-Saidi K, Deussing JM, Parsons CG.

Neuropharmacology. 2011 May;60(6):982-90. doi: 10.1016/j.neuropharm.2011.01.051. Epub 2011 Feb 12.

PMID:
21310164
19.

Memory impairment in transgenic Alzheimer mice requires cellular prion protein.

Gimbel DA, Nygaard HB, Coffey EE, Gunther EC, Laurén J, Gimbel ZA, Strittmatter SM.

J Neurosci. 2010 May 5;30(18):6367-74. doi: 10.1523/JNEUROSCI.0395-10.2010.

20.

Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior.

Selkoe DJ.

Behav Brain Res. 2008 Sep 1;192(1):106-13. doi: 10.1016/j.bbr.2008.02.016. Epub 2008 Feb 17. Review.

Items per page

Supplemental Content

Write to the Help Desk